Read the human liver-injury reports, understand why case counts cannot estimate personal risk, and know what to bring to a clinical assessment.
Ashwagandha-containing supplements have been linked to liver injury in people. Australia's medicines regulator describes the risk as very rare, but potentially severe. If you develop yellow skin or eyes, dark urine, vomiting, loss of appetite, unusual tiredness or abdominal pain while taking one, stop it and seek medical advice. People with current or previous liver problems should avoid it, according to the TGA's July 2026 safety alert.
For adults considering ashwagandha for sleep, stress or training, the useful questions are what the reports establish, how to recognize a possible reaction, and what information a clinician needs. A case count alone cannot answer your personal risk.
Two original case series illustrate why both reassurance and alarming percentages need context.
| Report | What was observed | What limits the conclusion |
|---|---|---|
| Iceland and US DILIN, 2020 | Five patients developed jaundice after starting ashwagandha-containing products. Their injury pattern was cholestatic or mixed, involving impaired bile flow or a combination of injury patterns. None developed liver failure. | Four also took other supplements. Causality assessments varied; hepatitis E testing was not performed. One patient was lost to follow-up. |
| Three Indian hospitals, 2023 | Eight selected patients had injury associated with single-ingredient ashwagandha products. Five had underlying chronic liver disease; three presented with acute-on-chronic liver failure and later died. | This was a retrospective hospital series. Six cases were rated probable and two possible by the authors' causality method. It was not a survey of supplement users. |
The Indian study excluded multiherbal products, other potentially hepatotoxic supplements or medicines, active alcohol use and competing causes of acute injury. That strengthens attribution within the selected cases. It does not establish how often injury occurs among everyone taking ashwagandha.
The earlier series also shows why recovery should not be promised on a fixed calendar. Symptoms began after 2–12 weeks, and itching and elevated bilirubin could persist for weeks. Its detailed results include one patient whose remaining bilirubin abnormality was documented as normalized nine months after injury onset. The paper's shorter summary should not become a universal recovery deadline.
These studies do not supply that estimate. To calculate incidence, researchers need a defined population of exposed users, a stated observation period and sufficiently complete case detection. Selecting five or eight people who already have suspected injury provides none of those denominators.
Likewise, three deaths among eight selected hospital patients is not a 37.5% mortality risk for supplement users. It describes outcomes in that series, with severe illness and underlying liver disease concentrated among the fatal cases. These are different questions: whether injury can occur, how severe selected cases were, and how frequently it occurs in users.
Regulator reports are safety signals rather than a census. Medsafe's June 2026 update described 24 New Zealand reports involving ashwagandha-containing products since 2010, including four liver-related reports. Those numbers do not reveal the total number exposed, establish causality in every report or provide an individual probability. Do not add counts from different publications without checking for overlapping cases.
No. In the Iceland/US series, analysis of available products confirmed ashwagandha and did not identify other known toxic compounds or trace metals. That did not make the clinical injury disappear or prove the responsible chemical mechanism.
The Indian series also included single-ingredient products and tested a subset of retrieved preparations. Those findings cannot certify an untested bottle or establish that every formulation has the same risk. Neither series determines a universally safe dose, extract, brand or cycling schedule.
A product-quality question and a suspected adverse reaction need different responses. Keep the label and lot information, but do not delay clinical assessment while waiting for a supplier's certificate or replacement.
The TGA distinguishes sudden vomiting or diarrhoea after only one or two doses from liver injury: an acute gastrointestinal reaction may explain it, but it still advises stopping use and seeing a doctor. Symptoms alone cannot settle the cause. Do not use the timing to dismiss jaundice or dark urine, or assume every stomach symptom proves liver damage.
Short trials also cannot settle long-term safety. The NIH Office of Dietary Supplements notes that many trials tolerated use for about three months, while evidence over many months or years is lacking. It also identifies thyroid and medication-interaction concerns. A reassuring short trial does not erase subsequently reported harms.
Help the clinician reconstruct the exposure rather than guessing which ingredient is responsible:
This checklist follows the case reports' need to assess exposure and competing explanations; it is not a diagnosis or a home testing protocol. The relevant next step for a suspected reaction is clinical assessment. For other research claims, our guide to checking human evidence explains how to separate a study's participants and outcomes from broader marketing claims.
Powered by BTST